The shadow of generic competition has long loomed around copyright’s iconic drug, Sildenafil, raising questions about the outlook of related drug ventures. While early years saw significant returns, the patent expiration has opened the way for less expensive copies, likely lowering revenue and creating a real hazard for stakeholders looking for s